Edition:
United States

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

169.00USD
23 Aug 2017
Change (% chg)

-- (--)
Prev Close
$169.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,154,755
52-wk High
$184.20
52-wk Low
$133.64

AMGN.OQ

Chart for AMGN.OQ

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN... (more)

Overall

Beta: 1.36
Market Cap(Mil.): $123,315.00
Shares Outstanding(Mil.): 729.67
Dividend: 1.15
Yield (%): 2.72

Financials

  AMGN.OQ Industry Sector
P/E (TTM): 15.37 78.70 32.82
EPS (TTM): 11.00 -- --
ROI: 11.98 3.22 14.97
ROE: 26.43 5.08 16.21

BRIEF-Amgen to present new data from the Repatha cardiovascular outcomes study

* Amgen to present new data from the Repatha cardiovascular outcomes study at ESC congress 2017 Source text for Eikon: Further company coverage:

Aug 21 2017

BRIEF-Amgen and Humana partner for improved health outcomes

* Amgen and Humana partner for improved health outcomes and efficiency Source text for Eikon: Further company coverage:

Aug 17 2017

BRIEF-Soros Fund Management LLC dissolves share stake in Alphabet, Amgen, American Airlines ‍​

* Soros Fund Management LLC dissolves share stake in Alphabet Inc class A shares ‍​

Aug 14 2017

BRIEF-Temasek Holdings takes stake in JPMorgan, Biogen, Celgene

* Temasek Holdings (Private) Ltd takes share stake in JPMorgan Chase & Co of 264,337 shares

Aug 14 2017

Fitch Downgrades AstraZeneca to 'A-'; Outlook Negative

(The following statement was released by the rating agency) LONDON, August 01 (Fitch) Fitch Ratings has downgraded UK-based pharmaceutical company AstraZeneca PLC's (AZ) Long-Term Issuer Default Rating (IDR) and senior unsecured rating to 'A-' from 'A'. The Outlook is Negative. The downgrade reflects AstraZeneca's increasing business risk as the pharmaceutical group transitions into next-generation therapies. The company's recent mixed late-stage pipeline developments in oncology - an increasing

Aug 01 2017

UPDATE 1-Express Scripts to cover Mylan's EpiPen, exclude rivals

NEW YORK, July 31 Pharmacy benefit manager Express Scripts Holding Co said on Monday it would favor drugmaker Mylan Inc's versions of the EpiPen lifesaving allergy treatment over the allergy auto-injectors of other companies.

Jul 31 2017

BRIEF-Amgen and Allergan submit biosimilar Biologics License application for ABP 980 to U.S. FDA

* Amgen and Allergan submit biosimilar Biologics License Application for ABP 980 to US Food and Drug Administration

Jul 31 2017

BRIEF-Amgen submits supplemental biologics license application for Prolia in glucocorticoid-induced osteoporosis

* Amgen submits supplemental biologics license application for Prolia® (denosumab) in glucocorticoid-induced osteoporosis

Jul 31 2017

BRIEF-Amgen sets quarterly dividend of $1.15/shr

* Sets quarterly dividend of $1.15per share Source text for Eikon: Further company coverage:

Jul 28 2017

Amgen gets fast FDA review for adding heart benefits to cholesterol drug label

Amgen Inc said on Thursday the U.S. Food and Drug Administration granted priority review to the company's request to add important heart safety data to the label of its expensive injectable cholesterol drug Repatha.

Jul 27 2017

Earnings vs. Estimates